On Friday, Beam Therapeutics Inc (NASDAQ: BEAM) opened higher 8.04% from the last session, before settling in for the closing price of $26.85. Price fluctuations for BEAM have ranged from $20.84 to $49.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 43297.50% annually for the last half of the decade. Company’s average yearly earnings per share was noted -174.65% at the time writing. With a float of $72.71 million, this company’s outstanding shares have now reached $82.56 million.
In an organization with 436 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 93.75%, operating margin of -52.25%, and the pretax margin is -40.67%.
Beam Therapeutics Inc (BEAM) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Beam Therapeutics Inc is 12.19%, while institutional ownership is 81.94%. The most recent insider transaction that took place on Nov 06 ’24, was worth 1,347,050. In this transaction President of this company sold 51,110 shares at a rate of $26.36, taking the stock ownership to the 109,150 shares. Before that another transaction happened on Oct 14 ’24, when Company’s President sold 51,110 for $26.27, making the entire transaction worth $1,342,752. This insider now owns 160,260 shares in total.
Beam Therapeutics Inc (BEAM) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -174.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 5.58% growth over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Check out the current performance indicators for Beam Therapeutics Inc (BEAM). In the past quarter, the stock posted a quick ratio of 5.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.76, a number that is poised to hit -1.27 in the next quarter and is forecasted to reach -4.84 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Let’s dig in a bit further. During the last 5-days, its volume was 1.73 million. That was better than the volume of 1.23 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 38.08%. Additionally, its Average True Range was 2.01.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 70.60%, which indicates a significant increase from 67.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.40% in the past 14 days, which was higher than the 69.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $25.68, while its 200-day Moving Average is $25.97. However, in the short run, Beam Therapeutics Inc’s stock first resistance to watch stands at $29.90. Second resistance stands at $30.78. The third major resistance level sits at $32.36. If the price goes on to break the first support level at $27.43, it is likely to go to the next support level at $25.85. Assuming the price breaks the second support level, the third support level stands at $24.97.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
There are currently 82,806K shares outstanding in the company with a market cap of 2.60 billion. Presently, the company’s annual sales total 377,710 K according to its annual income of -132,530 K. Last quarter, the company’s sales amounted to 14,270 K and its income totaled -96,670 K.
